Last reviewed · How we verify
Paprizumab combined with cisplatin and 5-FU
Paprizumab combined with cisplatin and 5-FU is a Small molecule drug developed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. It is currently FDA-approved.
At a glance
| Generic name | Paprizumab combined with cisplatin and 5-FU |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paprizumab combined with cisplatin and 5-FU CI brief — competitive landscape report
- Paprizumab combined with cisplatin and 5-FU updates RSS · CI watch RSS
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University portfolio CI
Frequently asked questions about Paprizumab combined with cisplatin and 5-FU
What is Paprizumab combined with cisplatin and 5-FU?
Paprizumab combined with cisplatin and 5-FU is a Small molecule drug developed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.
Who makes Paprizumab combined with cisplatin and 5-FU?
Paprizumab combined with cisplatin and 5-FU is developed and marketed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (see full Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University pipeline at /company/sun-yat-sen-memorial-hospital-of-sun-yat-sen-university).
What development phase is Paprizumab combined with cisplatin and 5-FU in?
Paprizumab combined with cisplatin and 5-FU is FDA-approved (marketed).